Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company, announced on March 18, 2024, that it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). This comes after receiving written notice on March 15, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq). The company’s focus lies in developing innovative medicines in areas of significant unmet medical need in oncology, particularly in using (Z)-endoxifen to prevent and treat breast cancer.
In the preceding 12 months ending in the third quarter of 2023, Atossa Therapeutics Inc reported a cumulative net loss of $-30 million, resulting in a negative return on investment (ROI) of -27.47%.
Comments